Home/Pipeline/JNJ-2113

JNJ-2113

Plaque Psoriasis

Phase 3Active

Key Facts

Indication

Plaque Psoriasis

Phase

Phase 3

Status

Active

Company

Johnson & Johnson

About Johnson & Johnson

Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.

View full company profile

Therapeutic Areas

Oncology Immunology Neuroscience Cardiopulmonary Cardiovascular Orthopaedics Surgery Vision

Other Plaque Psoriasis Drugs

Drug	Company	Phase	Status
Piclidenoson (CF101)	Can Fite Biopharma	Phase III	Active
Psoriasis Trial	Clinical Investigation Specialists	Not Specified	Actively Recruiting
ZL-1102 (CB001)	Crescendo Biologics	Phase 2	Active (Licensed to Zai Lab)
AX-158	Artax Biopharma	Phase 2	Active
VTAMA® (tapinarof)	Roivant Sciences	Approved	Launched (Asset acquired by Organon, 2024)
Wynzora	Almirall	Marketed	Commercial Growth
JNJ-81201887 (via Janssen)	OmniAb	Approved	Approved in EU